International expert panel review for the use of resmetirom and semaglutide in the management of MASH-related fibrosis: clinical practice update.

Studied

An expert-panel review of resmetirom and semaglutide in metabolic liver disease with significant fibrosis.

Who / model

Research and guidance concerning noncirrhotic metabolic dysfunction-associated steatohepatitis with significant liver fibrosis. This is a review, not a newly enrolled patient cohort.

Studied dose & schedule

Dose and schedule have not yet been extracted for this summary.

Found

The panel brings together trial data, medicine labels and clinical experience to discuss diagnosis, treatment selection, monitoring and response assessment. The abstract reports no new effect sizes or head-to-head comparison.

Limits

The proposed care framework is expected to change as long-term outcome data become available. It should not be read as new experimental proof for combining the medicines.

Read summary source ↗ · Prepared 9/15/2026 · AI-assisted, source-based summary